For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

CEO David Veitch | Half-year 2020 Update

Play

News

Jan 11. 2021

Basilea reports preliminary 2020 revenue and portfolio progress

Jan 07. 2021

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

Nov 25. 2020

Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (Cresemba®) in invasive aspergillosis in China

Nov 06. 2020

Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and hospital-acquired pneumonia

News Archive

Half-Year Report 2020

Download English
Download German

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures

Located in the heart of the life-sciences hub Basel

Play